Chunki Fong1, Pedro Mateu-Gelabert2, Courtney Ciervo2, Benjamin Eckhardt3, Yesenia Aponte-Melendez2, Shashi Kapadia4, Kristen Marks4. 1. CUNY Graduate School of Public Health and Health Policy, Institute for Implementation Science in Population Health (ISPH) 55 West 125th Street, New York, NY 10027, USA. Electronic address: chunki.fong@sph.cuny.edu. 2. CUNY Graduate School of Public Health and Health Policy, Institute for Implementation Science in Population Health (ISPH) 55 West 125th Street, New York, NY 10027, USA. 3. NYU School of Medicine, 550 First Avenue, New York, NY, 10016, USA. 4. Weill Cornell Medicine, 1305 York Ave 4th Floor, New York, NY, 10021, USA.
Abstract
BACKGROUND: Stigmatizing attitudes towards people who use drugs (PWUD) impact their access and retention in health care. Current measures of PWUD stigma in medical settings are limited. Therefore, we developed and validated theMedical Provider Stigma Experienced by PWUD (MPS-PWUD) scale. METHODS: As part of an ongoing clinical trial, we recruited HCV RNA positive people who inject drugs in New York City. Based on 164 participants, principal component analysis (PCA) was conducted on fifteen stigma items answered on a 5-point Likert scale. We evaluated internal consistency using Cronbach's alpha coefficient and assessed construct validity by comparing stigma levels with willingness to communicate health concerns with medical providers and likelihood to seek HCV treatment. RESULTS: PCA identified a 9-item scale with two components of stigmatization that explained 60.8 % of the total variance and overall high internal consistency (alpha = 0.90). Theenacted stigma (alpha = 0.90) consisted of 6 scale items related to the medical providers' stigmatizing actions or perceptions. The internalized stigma component (alpha = 0.84) included 3 scale items related to PWUD's shame or drug use disclosure. As hypothesized, higher levels of either stigma were associated with less likelihood to openly communicate with medical providers (p < 0.005). Participants with a higher level of enacted stigma were less likely to seek HCV treatment (p = 0.011). CONCLUSIONS: The validated MPS-PWUD scale could help healthcare providers, harm reduction services and researchers measure stigma experienced by PWUD in medical settings in efforts to minimize the impact of stigma on limiting access to and retention of care for PWUD. Published by Elsevier B.V.
BACKGROUND: Stigmatizing attitudes towards people who use drugs (PWUD) impact their access and retention in health care. Current measures of PWUD stigma in medical settings are limited. Therefore, we developed and validated theMedical Provider Stigma Experienced by PWUD (MPS-PWUD) scale. METHODS: As part of an ongoing clinical trial, we recruited HCV RNA positive people who inject drugs in New York City. Based on 164 participants, principal component analysis (PCA) was conducted on fifteen stigma items answered on a 5-point Likert scale. We evaluated internal consistency using Cronbach's alpha coefficient and assessed construct validity by comparing stigma levels with willingness to communicate health concerns with medical providers and likelihood to seek HCV treatment. RESULTS: PCA identified a 9-item scale with two components of stigmatization that explained 60.8 % of the total variance and overall high internal consistency (alpha = 0.90). Theenacted stigma (alpha = 0.90) consisted of 6 scale items related to the medical providers' stigmatizing actions or perceptions. The internalized stigma component (alpha = 0.84) included 3 scale items related to PWUD's shame or drug use disclosure. As hypothesized, higher levels of either stigma were associated with less likelihood to openly communicate with medical providers (p < 0.005). Participants with a higher level of enacted stigma were less likely to seek HCV treatment (p = 0.011). CONCLUSIONS: The validated MPS-PWUD scale could help healthcare providers, harm reduction services and researchers measure stigma experienced by PWUD in medical settings in efforts to minimize the impact of stigma on limiting access to and retention of care for PWUD. Published by Elsevier B.V.
Entities:
Keywords:
People who use drugs; Stigma in medical settings; Stigma scale
Authors: Anil G Suryaprasad; Jianglan Z White; Fujie Xu; Beth-Ann Eichler; Janet Hamilton; Ami Patel; Shadia Bel Hamdounia; Daniel R Church; Kerri Barton; Chardé Fisher; Kathryn Macomber; Marisa Stanley; Sheila M Guilfoyle; Kristin Sweet; Stephen Liu; Kashif Iqbal; Rania Tohme; Umid Sharapov; Benjamin A Kupronis; John W Ward; Scott D Holmberg Journal: Clin Infect Dis Date: 2014-08-11 Impact factor: 9.079
Authors: Alice K Asher; Carmen J Portillo; Bruce A Cooper; Carol Dawson-Rose; David Vlahov; Kimberly A Page Journal: Subst Use Misuse Date: 2016-05-24 Impact factor: 2.164
Authors: Anne L Stangl; Valerie A Earnshaw; Carmen H Logie; Wim van Brakel; Leickness C Simbayi; Iman Barré; John F Dovidio Journal: BMC Med Date: 2019-02-15 Impact factor: 8.775
Authors: Ashly E Jordan; Carmen L Masson; Pedro Mateu-Gelabert; Courtney McKnight; Nicole Pepper; Katie Bouche; Laura Guzman; Evan Kletter; Randy M Seewald; Don C Des-Jarlais; James L Sorensen; David C Perlman Journal: Harm Reduct J Date: 2013-06-20
Authors: Sarah K Calabrese; David A Kalwicz; Djordje Modrakovic; Valerie A Earnshaw; E Jennifer Edelman; Samuel R Bunting; Ana María Del Río-González; Manya Magnus; Kenneth H Mayer; Nathan B Hansen; Trace S Kershaw; Joshua G Rosenberger; Douglas S Krakower; John F Dovidio Journal: AIDS Behav Date: 2021-11-09
Authors: Yesenia Aponte-Melendez; Pedro Mateu-Gelabert; Chunki Fong; Benjamin Eckhardt; Shashi Kapadia; Kristen Marks Journal: Harm Reduct J Date: 2021-11-24
Authors: Magdalena Harris; Adam Holland; Dan Lewer; Michael Brown; Niamh Eastwood; Gary Sutton; Ben Sansom; Gabby Cruickshank; Molly Bradbury; Isabelle Guest; Jenny Scott Journal: BMC Med Date: 2022-04-14 Impact factor: 8.775